Charlestrad3r
Long

Data due soon and ready to breakout

NASDAQ:FPRX   FIVE PRIME THERAPEUTICS
Catalysts
FPA144 + chemo Phase 3 futility analysis due 1H 2020
FPA150 Phase 1b Ovarian cancer data due 1H 2020
Cabiralizumab (FPA008) and Opdivo (nivolumab) Phase 2 Data due 2H 2020

- High hedge fund buying in December -
BVF Partners holds a 10% ownership, Frpx Ranks 22 in their portfolio
RENAISSANCE TECHNOLOGIES holds a 3.6% stake in the company

Comments

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out